Omniox Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

Omniox General Information

Description

Developer of novel biologics designed to provide meaningful therapeutic benefit to patients. The company's biologics are engineered to deliver oxygen safely to hypoxic tissues, where abnormally low oxygen levels drive disease pathology and worsen patient outcomes and by specifically oxygenating pathologically hypoxic tissues they restore normal tissue function with the potential for improved outcomes and patient cures, enabling healthcare professionals to pioneer innovative oxygen-based therapies that restore health to patients.

Contact Information

Website
www.omniox.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Drug Discovery
Primary Office
  • 181 2nd Street
  • San Francisco, CA 94105
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Omniox Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Secondary Transaction - Private 28-Jul-2022 000.00 Completed Pre-Clinical Trials
12. Debt - PPP 28-Apr-2020 000.00 Completed Pre-Clinical Trials
11. Grant 01-Sep-2018 00.000 000.00 Completed Startup
10. Later Stage VC (Series D) 23-Mar-2018 0000 000.00 00000 Completed Pre-Clinical Trials
9. Grant 01-May-2017 00000 000.00 Completed Pre-Clinical Trials
8. Accelerator/Incubator 07-Feb-2017 000.00 Completed Pre-Clinical Trials
7. Grant 09-Oct-2014 00.00 000.00 Completed Pre-Clinical Trials
6. Later Stage VC (Series C) 18-Jun-2014 00.00 000.00 000.00 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 24-Jun-2013 $3.04M $4.05M 000.00 Completed Pre-Clinical Trials
4. Later Stage VC (Series A) 06-Jul-2012 $1M $1M 000.00 Completed Pre-Clinical Trials
To view Omniox’s complete valuation and funding history, request access »

Omniox Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series B 4,346,382 $0.000100 8% $0.71 $0.71 1x $0.71 3.9%
Series A 3,150,959 $0.000100 8% $0.57 $0.57 1x $0.57 2.83%
To view Omniox’s complete cap table history, request access »

Omniox Patents

  • 35

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Omniox Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2018046873-A Polymeric forms of h-nox proteins Active 04-Jan-2018
CA-3014651-A1 Modulation of hypoxia associated with stroke Inactive 16-Feb-2016 0000000000
EP-3416673-A1 Modulation of hypoxia associated with stroke Active 16-Feb-2016 0000000000
EP-3416673-B1 Modulation of hypoxia associated with stroke Active 16-Feb-2016 0000000000
ES-2939181-T3 Modulation of hypoxia associated with stroke Active 16-Feb-2016 A61K38/164
To view Omniox’s complete patent history, request access »

Omniox Executive Team (6)

Name Title Board Seat Contact Info
Jonathan Winger Ph.D Co-Founder, Chief Executive Officer & Board Member
Stephen Cary Ph.D Co-Founder, President & Board Member
Julia Simmons Senior Director & Controller
Michael Marletta Ph.D Co-Founder
Laurence Marton Executive Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Omniox Board Members (6)

Name Representing Role Since
Cory Freedland Ph.D Self Board Member 000 0000
Jonathan Winger Ph.D Omniox Co-Founder, Chief Executive Officer & Board Member 000 0000
Laurence Marton Omniox Executive Chairman 000 0000
Stephen Cary Ph.D Omniox Co-Founder, President & Board Member 000 0000
You’re viewing 4 of 6 board members. Get the full list »

Omniox Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Omniox Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Casdin Capital Hedge Fund Minority 000 0000 000000 0
EcoR1 Capital Venture Capital Minority 000 0000 000000 0
Emerson Electric Corporation Minority 000 0000 000000 0
Plug and Play Tech Center Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial